2I3 Stock Overview
A technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Champions Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.76 |
| 52 Week High | US$6.25 |
| 52 Week Low | US$3.36 |
| Beta | 0.27 |
| 1 Month Change | -11.03% |
| 3 Month Change | 12.80% |
| 1 Year Change | -15.00% |
| 3 Year Change | -31.51% |
| 5 Year Change | -36.53% |
| Change since IPO | 27.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2I3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.5% | 1.2% |
| 1Y | -15.0% | 1.2% | 10.1% |
Return vs Industry: 2I3 underperformed the German Life Sciences industry which returned 1.2% over the past year.
Return vs Market: 2I3 underperformed the German Market which returned 10.1% over the past year.
Price Volatility
| 2I3 volatility | |
|---|---|
| 2I3 Average Weekly Movement | 12.3% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2I3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2I3's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 210 | Ronnie Morris | www.championsoncology.com |
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
Champions Oncology, Inc. Fundamentals Summary
| 2I3 fundamental statistics | |
|---|---|
| Market cap | €128.48m |
| Earnings (TTM) | -€580.60k |
| Revenue (TTM) | €52.01m |
2.5x
P/S Ratio-221.3x
P/E RatioIs 2I3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2I3 income statement (TTM) | |
|---|---|
| Revenue | US$53.57m |
| Cost of Revenue | US$29.60m |
| Gross Profit | US$23.97m |
| Other Expenses | US$24.57m |
| Earnings | -US$598.00k |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 44.75% |
| Net Profit Margin | -1.12% |
| Debt/Equity Ratio | 0% |
How did 2I3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 21:56 |
| End of Day Share Price | 2024/12/13 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Champions Oncology, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Bienstock | B. Riley Wealth |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Knight | Janney Montgomery Scott LLC |